Summary
The home competitive environment has a powerful effect on companies — shaping skills, strategies, and performance outside the home environment. Government industrial policies, such as pharmaceutical pricing regulations, affect companies primarily through shaping the nature of the home environment. Successful competitive environments (such as the UK) exhibit higher average drug prices and an internal structure of prices that favour significant innovators, discourage minor products, and provide a shield against foreign competitors. Poor competitive environments (such as France) exhibit low average prices and an internal price structure that favours weak local companies producing imitative or minor products.
Similar content being viewed by others
References
Thomas LG. Spare the rod and spoil the industry: vigorous competition and vigorous regulation promote global competitive advantage. New York University working paper. December 1990
Thomas LG. Price regulation, industry structure, and innovation: an international comparison of pharmaceutical industries. Work in progress, 1991
Chew R, Teeling-Smith G, Wells R. Pharmaceuticals in seven nations, Office of Health Economics, London, 1985
Davis R, Thomas LG. Direct estimation of synergy: a new approach to the diversity—performance debate. New York University working paper, October, 1990
Porter ME. The competitive advantage of nations, Free Press, New York, 1990
Thomas LG. Regulation and firm size: FDA impacts on innovation. Rand Journal of Economics, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thomas, L.G. Price Regulation, Industry Structure and Innovation. Pharmacoeconomics 1 (Suppl 1), 9–12 (1992). https://doi.org/10.2165/00019053-199200011-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199200011-00005